Elsevier

Urology

Volume 44, Issue 5, November 1994, Pages 711-718
Urology

Adult urology
Relationship of tumor DNA-ploidy toserum prostate-specific antigen doubling time after radiotherapy for prostate cancer

https://doi.org/10.1016/S0090-4295(94)80213-0Get rights and content

Abstract

Objectives.

DNA-ploidy is a strong prognostic factor for prostate cancer patientstreated with definitive external beam radiotherapy. Using DNA/nuclear protein flow cytometry, three prognostic groups based on DNA-ploidy were identified: from good to poor, these are diploid, near-diploid, and nondiploid tumors. Since recent evidence indicates that the rate at which prostate-specific antigen (PSA) increases in the presence of biochemical failure is predictive of the time to clinical relapse, we examined the relationship between DNA-ploidy and PSA doubling time (PSA-DT).

Methods.

Formalin-fixed paraffin-embedded tissues from 76 patients treated at M.D. Anderson Cancer Center with definitive radiotherapy alone were analyzed for ploidy using DNA/nuclear protein flow cytometry. Of these, 24 of the 27 patients with a rising PSA profile had three or more post-treatment PSA values from which the PSA-DTs were calculated. PSA-DTs were estimated using nonlinear regression techniques.

Results.

The average PSA-DT for the 24 patients in this cohort was 11.3 ± 10.5 months(±SD) with a median of 8.4 months. Diploidy (n = 3) was associated with a PSA-DT of 27.0 ± 22.8 months, near-diploidy (n = 7) with a PSA-DT of 12.2 ± 5.7 months, and nondiploidy (n = 14) with a PSA-DT of 7.5 ± 5.7 months (p = 0.004, Spearman rank test). Stage, grade, and pretreatment PSA, as well as the endpoints of local control, freedom from metastases, and freedom from any relapse, did not correlate significantly with PSADT values. However, when patients were subdivided by PSA-DT into those with values 10 months or less (n = 14) and those more than 10 months (n = 10), there was a correlation with 3-year actuarial freedom from relapse: 28% and 74%, respectively (p < 0.01, log-rank). This subdivision of PSA DT also correlated with DNA ploidy (p = 0.03, chi-square) and stage (p = 0.04).

Conclusions.

The results show that there is a significant correlation of DNA-ploidy with PSA-DT Diploidy was associated with the longest PSADTs, near-diploidy with intermediate PSA-DTs, and nondiploidy with short PSA-DTs. Patients with short PSA-DTs also had significantly higher actuarial rates of disease relapse at 3 years. These data confirm that PSA-DT is a strong predictor of tumor behavior and that patients who have nondiploid tumors probably require more aggressive, combined modality, treatment.

References (31)

  • SongJ. et al.

    Nuclear deoxyribonucleic acid content measured by static cytometry: important prognostic association for patients with clinically localizedprostate carcinoma treated by external beam radiotherapy

    J Urol

    (1992)
  • GauwitzM.D. et al.

    The prognostic significance of DNA ploidy in clinically localized prostate cancer treated with radiation therapy

    Int J Radiat Oncol Biol Phys

    (1994)
  • NativO. et al.

    Stage C prostatic adenocarcinoma: flow cytometric nuclear DNA ploidy analysis

    Mayo Clin Proc

    (1989)
  • ZagarsG.K. et al.

    Prostatespecific antigen and external beam radiotherapy in prostate cancer

    Cancer

    (1991)
  • RitterM.A. et al.

    Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer

    J Clin Oncol

    (1992)
  • Cited by (23)

    View all citing articles on Scopus

    This study was supported in part by grants CA-06294 and CA-16672 awarded by the National Cancer Institute, U.S. Department of Health and Human Services; by the Katherine Unsworth Lead Annuity Trust; and by a University of Texas M.D. Anderson Executive Council Grant.

    View full text